Scilex Holding (SCLX) Preferred Stock Liabilities (2021 - 2022)
Scilex Holding (SCLX) posted quarterly Preferred Stock Liabilities of $101.3 million for Q3 2022, down 27.33% year-over-year from $139.4 million in Q3 2021, and up 1.1% on a QoQ basis from $100.2 million in Q2 2022.
Scilex Holding (SCLX) Preferred Stock Liabilities (2021 - 2022) Analysis & Trends
Scilex Holding (SCLX) has reported Preferred Stock Liabilities for 2 consecutive years, with $101.3 million the latest figure, recorded in Q3 2022.
- In Q3 2022, Preferred Stock Liabilities fell 27.33% year-over-year to $101.3 million; the TTM figure through Sep 2022 stood at $101.3 million (down 27.33% YoY), while the FY2021 annual figure was $139.4 million, changed N/A from the prior year.
- Preferred Stock Liabilities came in at $101.3 million for Q3 2022 at Scilex Holding, up from $100.2 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $140.4 million in Q1 2022, with the low at $13.4 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Scilex Holding | 54.30 Mn | -95.62 Mn | 4.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 101.29 Mn |
| Jun 30, 2022 | 100.19 Mn |
| Mar 31, 2022 | 140.42 Mn |
| Dec 31, 2021 | 139.38 Mn |
| Sep 30, 2021 | 139.38 Mn |
| Jun 30, 2021 | 13.39 Mn |
| Mar 31, 2021 | 139.38 Mn |